• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
SMMT

SMMT

Summit Therapeutics Inc.

NASDAQHealthcareBiotechnologyUS

USD15.07

+0.21 (+1.41%)

Rating:C

Company Profile

CEO

Robert W. Duggan

IPO Date

2015-03-05

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$14.75

Prev. Close

$14.86

Day Low

$14.27

Day High

$15.11

52W Low

$13.83

52W High

$30.98

Market Cap

$11.68B

Volume

4.35M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

33.6%

Avg Negative

1.9%

Avg Neutral

64.5%

News Feed

Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole

GlobeNewsWire·7/12/2021·↑ positive

Summit Therapeutics PLC (SMMT) Moves 17.4% Higher: Will This Strength Last?

Zacks Investment Research·5/19/2021·↑ positive

Summit Therapeutics (SMMT): 26.62% Increase Explanation

Pulse2
·5/17/2021
·↑ positive

These 2 Nasdaq Stock Winners Could Change the World

The Motley Fool·5/17/2021·↑ positive

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021

GlobeNewsWire·5/17/2021·↑ positive

Summit Therapeutics Announces Closing of $75 Million Rights Offering

GlobeNewsWire·5/12/2021·↑ positive

Summit Therapeutics: Whether It's A Go-Private Candidate

Seeking Alpha·5/11/2021·↑ positive

Summit Therapeutics' Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering

GlobeNewsWire·5/5/2021·↓ negative

Summit Therapeutics Announces Commencement of Rights Offering

GlobeNewsWire·4/21/2021·↑ positive

Summit Therapeutics Announces Rights Offering

GlobeNewsWire·3/26/2021·↑ positive